This comes at a time when cannabis use among boomers is, well, booming. The number of Americans aged 65+ using cannabis for medical purposes rose from 4.8% in 2021 to 7% in 2023, a 46% jump in just ...

Canopy Growth › Buying a stock for a mere $2 may sound cheap on the surface, but that's only the case if there are good ...

Investing in cannabis stocks is back in focus as regulatory progress and expanding medical use steadily lift demand. The ...

In December, President Donald Trump in an executive order told his attorney general to expediate a rulemaking process related to rescheduling marijuana as a less-dangerous drug.

Recent regulatory developments have improved the landscape of the cannabis industry in the U.S. Canopy Growth and Aurora Cannabis are two leaders in the Canadian market that could turn their attention ...

U.S. cannabis stocks appear to have completed their post-Executive Order pullback, says Beacon Securities analyst Russell ...

Beacon Securities analyst Russell Stanley said in a January 15 industry update that the post-correction recovery in U.S.

Many cannabis stocks have experienced significant growth over the past six months. For instance, shares of Tilray Brands ...

Dec 18 (Reuters) - Shares of some cannabis firms fell between 3% and 12% at Thursday's close, erasing previous gains from the session, after U.S. President Donald Trump signed an executive order ...

U.S. and Canadian names rally. But one expert notes 'the rescheduling process has faced many hurdles in the past.' Shares of Tilray jumped more than 27% on Tuesday. Shares of U.S. and Canadian ...